Solicitudes publicadas en los últimos 90 días / Applications published in the last 90 days
NºPublicación: EP3126840A1 08/02/2017
PASTEUR INSTITUT [FR]
UNIV PARIS-SUD [FR]
CENTRE HOSPITALIER DE VERSAILLES [FR]
ASSIST PUBLIQUE H\u00D4PITAUX DE PARIS [FR]
The present invention relates to the field of Clostridium difficileinfections. Methods of diagnosing, treating and preventing Clostridium difficile-associated disease and recurrent CDAD are disclosed herein.
NºPublicación: US2017030907A1 02/02/2017
UTI LIMITED PARTNERSHIP [CA]
The present invention relates to an apparatus comprising TLR-4 based electrochemical biosensor and a method for using the same to detect the presence of gram-negative bacteria or lipopolysaccharide in a sample. In one particular embodiment, the apparatus comprises an electric conducting solid substrate surface having a monolayer of a mixture of linkers each of which has a first functional group that is attached to the surface of said electric conducting solid substrate. The mixture of linkers comprises tethering-linkers and spacer-linkers such that the amount of spacer-linkers is equal to or greater than that of the tethering-linkers. The tethering linker also comprises a second functional group that is used to attach a toll-like receptor 4 (TLR-4).
NºPublicación: US2017028046A1 02/02/2017
IDEMITSU KOSAN CO [JP]
NAT CENTER FOR GLOBAL HEALTH AND MEDICINE [JP]
The present invention provides an agent for controlling colibacillosis including a fusion protein comprising a subunit of Shiga toxin and a subunit of Escherichia coli heat-labile toxin.
NºPublicación: US2017030908A1 02/02/2017
CENTRE NAT DE LA RECH SCIENT (CNRS) [FR]
UNIVERSIT\u00C9 PARIS-SUD [FR]
The present invention concerns a method for detecting specifically living bacteria of a given category of bacteria in a sample comprising bacteria, the method comprising the steps of: a) incubating said bacteria of said sample with an analog of a monosaccharide compound, said monosaccharide being an endogenous monosaccharide residue of glycans of the outer membrane of such given category of bacteria, the said endogenous monosaccharide residue comprising an ulosonic acid or ulosonate salt residue, the said analog of a monosaccharide compound being a modified monosaccharide substituted at a given position by a first reactive chemical group capable to react with a second reactive group of a detectable molecule, and b) contacting said bacteria with a said detectable molecule comprising a said second reactive group, for generating the reaction of said first reactive group of said analog residue incorporated within said glycans of the outer membrane of said bacteria with said second reactive group of said detectable, and c) detecting whether said bacteria comprise said detectable molecule bound to the glycans of their outer membrane.
NºPublicación: US2017029864A1 02/02/2017
RAPID MICRO BIOSYSTEMS INC [US]
The invention enables efficient, rapid, and sensitive enumeration of living cells by detecting microscopic colonies derived from in situ cell division using large area imaging. Microbial enumeration tests based on the invention address an important problem in clinical and industrial microbiology—the long time needed for detection in traditional tests—while retaining key advantages of the traditional methods based on microbial culture. Embodiments of the invention include non-destructive aseptic methods for detecting cellular microcolonies without labeling reagents. These methods allow for the generation of pure cultures which can be used for microbial identification and determination of antimicrobial resistance.
NºPublicación: EP3122773A2 01/02/2017
GHOSH SAMBUDDHA [IN]
The present disclosure relates to camel id antibodies that inhibit growth, and colonization of Salmonella serovars. The present disclosure also relates to a modified Lactobacillus as a delivery vehicle for controlling salmonella in a host organism.
NºPublicación: BR112013029417A2 31/01/2017
MATRIVAX INC [MC]
The present invention relates to immunogenic compositions containing one or more antigens of interest, one or more carrier proteins, and one or more polycations, wherein the antigen of interest is entrapped with cross-linked carrier protein matrix and one or more polycations, methods of making such vaccines, and methods of vaccine administration.
NºPublicación: NZ629535A 27/01/2017
ABSYNTH BIOLOGICS LTD
A vaccine composition comprising a Clostridium difficle polypeptide represented by SEQ ID NO: 119 (GCP) and SEQ ID NO: 149 (Div1B) (sequences as defined in the specification).
NºPublicación: HK1217973A1 27/01/2017
IMICROQ S L [ES]
The present specification discloses methods of detecting a pathogen of interest and components useful in carrying out these methods, including a pre-enrichment media, and enrichment media and a detection solution.
NºPublicación: WO2017012659A1 26/01/2017
CURETIS GMBH [DE]
The invention relates to a method of determining an infection of a patient with Salmonella species potentially resistant to antimicrobial drug treatment, a method of selecting a treatment of a patient suffering from an antibiotic resistant Salmonella infection, and a method of determining an antibiotic resistance profile for bacterial microorganisms of Salmonella species, as well as computer program products used in these methods. In an exemplary method, a sample (1) is used for molecular testing (2), and then a molecular fingerprint (3) is taken. The result is then compared to a reference library (4), and the result (5) is reported.
NºPublicación: WO2017013217A2 26/01/2017
CURETIS GMBH [DE]
The invention relates to a method of determining an infection of a patient with Salmonella species potentially resistant to antimicrobial drug treatment, a method of selecting a treat- ment of a patient suffering from an antibiotic resistant Sal- monella infection, and a method of determining an antibiotic resistance profile for bacterial microorganisms of Salmonella species, as well as computer program products used in these methods. In an exemplary method, a sample 1 is used for mo- lecular testing 2, and then a molecular fingerprint 3 is tak- en. The result is then compared to a reference library 4, and the result 5 is reported.
NºPublicación: WO2017014963A1 26/01/2017
ENVIROLOGIX INC [US]
The present invention features rapid and accurate methods for detecting Salmonella (e.g., in a food product, environmental sample, biological sample or other material).
NºPublicación: JP2017502692A 26/01/2017
The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
NºPublicación: US2017021015A1 26/01/2017
SIRARD JEAN-CLAUDE [FR]
INSERM (INSTITUT NAT DE LA SANT\u00C9 ET DE LA RECH M\u00C9DICALE) [FR]
PASTEUR INSTITUT [FR]
The present invention relates to novel peptide compounds derived from flagellin originating from Salmonelle enterica that exhibit an in vivo immune adjuvant activity.
NºPublicación: US2017021005A1 26/01/2017
UNIV YALE [US]
The invention provides compositions and methods for using PltA, PltB, CdtB, or a mutant thereof, in inducing or enhancing an immune response.
NºPublicación: BR112013029677A2 24/01/2017
CJ CHEILJEDANG CORP [KR]
The present invention relates to avirulent Salmonella Gallinarum variants by inactivating virulence gene clusters of Salmonella Gallinarum (SG), a main pathogen of avian salmonellosis, and various uses thereof notably in the production of Salmonella-specific lytic bacteriophages, pharmaceutical compositions and feed additives.
NºPublicación: US2017014532A1 19/01/2017
UNIV MICHIGAN TECH [US]
The present invention provides various fluorescent conjugated polymers with a BODIPY-based backbone. The invention also provides methods of using the polymers of the invention, such as for imaging and detection of cells, tumors, bacteria and viruses.
NºPublicación: WO2017007852A1 12/01/2017
PROTEIN POTENTIAL LLC [US]
Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.
NºPublicación: WO2017006349A1 12/01/2017
BHARAT BIOTECH INT LTD [IN]
The present invention relates to the field of combined vaccine compositions which are effective against all forms of meningococcal diseases as well as typhoid fever. The vaccine formulations comprising antigens from capsular polysaccharides of Neisseria meningitidis A, Neisseria meningitidis C, Neisseria meningitidis Y, Neisseria meningitidis W135, Neisseria meningitidis X, Salmonella typhi Vi capsular polysaccharide (ViPs) or capsular ViPs conjugated to a carrier protein tetanus toxoid (ViPs-TT). This invention is also related to improved methods, especially the use of an improved feed media and an improved method of downstream processing and industrial purification of capsular polysaccharides. The vaccine is free of any animal component or alcohol and is in absolute compliance with respect to the religious sentiments of various ethnic groups. The composition is highly effective and stable, yet cost- effective and affordable, especially for lower-middle income and low-income countries.
NºPublicación: US2017008935A1 12/01/2017
US AGRICULTURE [US]
A novel, mutated Salmonella enterica serovar Typhimurium vaccine is generated and imparts protective immunity in vaccinated animals for a range of S. enterica serovars. The vaccine can be attenuated or inactivated, including bacterial ghosts or membrane fractions thereof. Immunogenic compositions are included in the invention and methods of generating an immune response.
NºPublicación: JP2017008055A 12/01/2017
Disclosed are synthetic nanocarrier compositions with separate adjuvant compositions as well as related methods.
NºPublicación: EP3114483A1 11/01/2017
YISSUM RES AND DEV COMPANY OF THE HEBREW UNIV OF JERUSALEM LTD [IL]
YEDA RES & DEV [IL]
A method of and device for detecting and diagnosing Pseudomonal aeruginosa in a gaseous, liquid or solid sample, employing Lux-R-like receptor-driven reporter cells.
NºPublicación: EP3115060A1 11/01/2017
VAXINNATE CORP [US]
Compositions that include Toll-like Receptor 5 agonists and at least a portion of at least one influenza antigen can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can be associated with particles and employed in the methods in relatively low doses to provide protective immunity to viral infection.
NºPublicación: GB2540130A 11/01/2017
INST OF TECH SLIGO [IE]
A composition for controlling bacterial infection in the gastrointestinal tract of an animal comprising an oxidoreductase enzyme and its corresponding oxidisable substrate which are capable of producing and releasing hydrogen peroxide in the gastrointestinal tract of an animal. Preferably the oxidoreductase enzyme is glucose oxidase. Preferably the oxidisable substrate is D-glucose. The composition may comprise a peroxide of an organic acid, preferably benzoyl peroxide. The composition may comprise L-cysteine. Preferably the composition may be in the form of granules coated with an enteric coating. Also claimed is a method for controlling bacterial infection of meat comprising administration of the composition to an animal for a period of time immediately prior to slaughtering the animal and processing its meat. Preferably the period of time is between 24 and 48 hours immediately before slaughter. Preferably the composition is administered to poultry. The bacterial infection may be caused by Campylobacter spp, Salmonella spp, or Cryptosporidium spp.
Nº publicación: PH12016502002A1 09/01/2017
CJ CHEILJEDANG CORP [KR]
The present invention relates to a novel bacteriophage FCJ26 (KCCM11464P) and a composition comprising the bacteriophage FCJ26 (KCCM11464P) as an active ingredient. In addition, the present invention relates to a method for preventing and/or treating an infectious disease due to Salmonella by using the bacteriophage FCJ26 (KCCM11464P) or the composition comprising same as an active ingredient.